From Stock Story: 2025-02-09 08:02:10

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) is set to report earnings tomorrow, with analysts expecting revenue to grow by 12.9% to $1.14 billion and adjusted earnings at $1.55 per share. Incyte beat revenue expectations last quarter but missed EPS estimates. Analysts have generally reconfirmed their estimates, despite Incyte missing revenue estimates three times in the last two years. Peers like Regeneron and AbbVie have already reported Q4 results, showing revenue growth and exceeding analyst expectations. Incyte’s stock price has increased by 7.5% in the last month, with an average analyst price target of $79.92.



Read more at Stock Story: Incyte (INCY) Reports Q4 Results Tomorrow